ライフサイエンスコーパス: were censored

1 hen schizophrenia onsets 3-5 years after smoking assessment were censored.

2 t metastases, second primary cancers, and deaths before LRR were censored.

3 o-treat analysis; data for participants who became pregnant were censored.

4 ts such as graft loss, patient death, and lost to follow-up were censored.

5 Births, maternal deaths, and induced abortions were censored.

6 Data for all patients were censored 1 year post-study or death, whichever came firs

7 Whereas 1975 patients received a KT and were censored, 1876 were on the waiting list at any time.

8 y where everyone with a prior history of any MACE before MI were censored and adjusted for follow-up times.

9 observing from a worldwide network of computers which texts were censored and which were not.

10 Patients were followed up until death and were censored at 5 years if they were still alive.

11 Data were censored at ART initiation.

12 Patients were censored at death or last follow-up.

13 Cases were censored at death or liver transplantation and had a med

14 Time-to-event analyses were censored at first date of new cancer event, last contact

15 Patients were censored at postdischarge emergency department encounter

16 analysis, when patients who received SCT in first remission were censored at SCT time, 2-year RFS was 53.3% (95% CI, 39%

17 A total of 1975 patients received a successful KT and were censored at that point, whereas 1876 were on the waiting

18 Patients who were alive at the last follow-up evaluation were censored at that time.

19 Women who experienced surgical menopause were censored at the date of surgery.

20 ithin 3 months of first intercourse with a male partner and were censored at the report of a second partner.

21 Results All patients in the N3I3 arm (n = 6) were censored at the time of analysis as a result of dose-lim

22 When participants were censored at the time of cointerventions (parathyroidecto

23 he primary analytic strategy in which participants (n = 33) were censored at the time of dropout, mean cumulative respons

24 d a hospitalization for a diagnosis of primary brain injury were censored at the time of hospitalization.

25 5% CI, 61 to 95) in the rabbit-ATG group (P=0.04) when data were censored at the time of stem-cell transplantation, and 9

26 tural history, patients undergoing aortic valve replacement were censored at the time of surgery (n=92).

27 Patients with missing data were censored at the time of withdrawal from the study or at

28 ed at 48 months (HR, 1.49; 95% CI, 1.05-2.11) or when women were censored at their first cardiovascular event (HR, 1.68;

29 Participants were censored at their first visit with a positive test resul

30 m birth and death dates; children living on March 31, 2013, were censored at their last clinical encounter.

31 Patients who continued, alive and relapse free, were censored at their last known follow-up.

32 in the standard care group had been lost to follow-up, and were censored at their last visit for the primary analysis.

33 Data for patients on treatment were censored at this timepoint.

34 who underwent liver transplantation without decompensation were censored at transplantation.

35 No patients were censored before 1 year (median follow-up period 438 days

36 Data were censored both at the time of transplantation (listed onl

37 icipants in the placebo group and 22 in the treatment group were censored, but all contributed data for the final analysi

38 Participants were censored for a new diagnosis of a uveitis-associated sys

39 Patients were censored for death with LVAD at the time of transplant o

40 Outcome data were censored if no CCHS encounters occurred for 2 consecutiv

41 (FCTA) at our center between April 2009 and May 2011; data were censored in June 2012.

42 Follow-up data were censored on December 13, 2011.

43 Patients were followed up until death or were censored on December 31, 2013.

44 men developed AIDS or died, and 170 survived AIDS-free and were censored on January 1, 1996, or lost to follow-up.

45 Patients lost to follow-up were censored on the date of their last follow-up.

46 ndary outcomes [eg, new non-recrudescent malaria infection] were censored on the last day of follow-up), and per-protocol

47 sychiatric setting for any mental disorder; 489,006 persons were censored owing to death; and 69,987 persons were censore

48 06 persons were censored owing to death; and 69,987 persons were censored owing to emigration.

49 is in which data for patients who underwent transplantation were censored, the benefit of midostaurin was consistent acro

50 Animal data were censored to simulate prospective monitoring at any momen